Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study

J Clin Psychopharmacol. 1997 Apr;17(2):97-101. doi: 10.1097/00004714-199704000-00006.

Abstract

The effects of short treatment (7 days) with the tricyclic antidepressant imipramine and the two selective serotonin reuptake inhibitors paroxetine and sertraline on the reactivity to inhalation of 35% CO2/65% O2 were compared in 70 panic patients who had positive responses to 35% CO2 inhalations. A double-blind, random, placebo-controlled design was applied. Each patient was given the 35% CO2 challenge on days 0 (before starting the treatment), 3, and 7. In the placebo group, there were no significant changes in the reactivity to 35% CO2 in the three sessions whereas there were significant similar reductions of reactivity to 35% CO2 in all three drug-treated groups. These results confirm the good reproducibility of 35% CO2 reactivity and the negligible effects of placebo on reactivity to CO2 and suggest that short treatments with imipramine, paroxetine, and sertraline decrease reactivity to 35% CO2, possibly as an expression of their antipanic properties.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Antidepressive Agents, Tricyclic / therapeutic use*
  • Anxiety / chemically induced
  • Carbon Dioxide / adverse effects
  • Double-Blind Method
  • Female
  • Humans
  • Imipramine / therapeutic use*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Panic Disorder / drug therapy*
  • Panic Disorder / psychology
  • Paroxetine / therapeutic use*
  • Placebos
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Sertraline / therapeutic use*

Substances

  • Antidepressive Agents, Tricyclic
  • Placebos
  • Serotonin Uptake Inhibitors
  • Carbon Dioxide
  • Paroxetine
  • Imipramine
  • Sertraline